Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3/10/25 16:43 | 3/6/25 | BBIO | Health | Drug | Pharmaceutical Preparations | Valantine Hannah | CA | D | 1 | S.d | -420 | 32.58 | 0 | -13 | 5 | D | ||||||||||||||||
3/7/25 18:09 | 3/5/25 | BBIO | Financ | InvAdv | Investment Advice | Kkr Genetic Disorder L.P. | NY | T | 1 | S | -197,760 | 32.96 | 0 | -6,000 | 19,261 | I | ||||||||||||||||
2/27/25 17:36 | 2/25/25 | BBIO | Health | Drug | Pharmaceutical Preparations | Stephenson Brian C | CA | O | CFO,Trea | 3 | S.d | -2,900 | 35.96 | 0 | -81 | 102 | D | |||||||||||||||
2/27/25 17:12 | 2/25/25 | BBIO | Health | Drug | Pharmaceutical Preparations | Kumar Neil | CA | DO | CEO | 3 | S.dm | -25,447 | 36.02 | 0 | -707 | 6,306 | I | |||||||||||||||
1/31/25 19:18 | 1/31/25 | BBIO | Health | Drug | Pharmaceutical Preparations | Viking Global Investors LP | CT | T | 1 | S | -106,990 | 34.90 | 0 | -3,066 | 22,055 | I |
D | Derivative transaction in filing (usually option exercise) |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
A | Amended filing |
E | Error detected in filing |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |